3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase NA
1
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Breast Neoplasms
320
Leukemia, Myeloid, Acute
266
Multiple Myeloma
227
Carcinoma, Non-Small-Cell Lung
224
Prostatic Neoplasms
202
Neoplasms
196
Lymphoma
191
Colorectal Neoplasms
184
Melanoma
179
Leukemia
170
Recurrence
164
Pancreatic Neoplasms
163
Precursor Cell Lymphoblastic Leukemia-Lymphoma
160
Lung Neoplasms
150
Glioblastoma
134
Neoplasm Metastasis
132
Lymphoma, Non-Hodgkin
128
Ovarian Neoplasms
123
Leukemia, Lymphocytic, Chronic, B-Cell
120
Myelodysplastic Syndromes
117
Lymphoma, Large B-Cell, Diffuse
110
Lymphoma, Mantle-Cell
108
Carcinoma, Hepatocellular
103
Lymphoma, Follicular
99
Stomach Neoplasms
96
Carcinoma, Renal Cell
89
Hodgkin Disease
88
Brain Neoplasms
88
Sarcoma
84
Burkitt Lymphoma
75
Interventions
regorafenib
1
Clinical Trials, Phase II as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
OTHER
×
Tertiary Lymphoid Structures
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled